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Open acca b s t r a c t
The effect of age or dose regimen on cholinesterase inhibition (ChEI) from chlorpyrifos (CPF) or CPF–oxon
(CPFO) was studied in Crl:CD(SD) rats. Rats were exposed to CPF by gavage in corn oil, rat milk (pups), or
in the diet (adults) or to CPFO by gavage in corn oil. Blood CPF/CPFO levels were measured. With acute
exposure, ChEI NOELs were 2 mg/kg CPF for brain and 0.5 mg/kg CPF for red blood cells (RBCs) in both
age groups. In pups, ChEI and blood CPF levels were similar using either milk or corn oil vehicles. Com-
pared to gavage, adults given dietary CPF (12 h exposure) had greater RBC ChEI, but lower brain ChEI at
corresponding CPF doses, indicating an effect of dose rate. With repeated CPF exposures, ChEI NOELs were
the same across ages (0.5 and 0.1 mg/kg/day for brain and RBCs, respectively). With CPFO dosing, the ChEI
NOELs were 0.1 mg/kg (acute) and 0.01 mg/kg/day (repeated doses) for RBCs with no ChEI in brain at
CPFO doses up to 0.5 (pup) or 10 mg/kg (adult) for acute dosing or 0.5 mg/kg/day for both ages with
repeat dosing. Thus, there were no age-dependent differences in CPF ChEI via acute or repeated expo-
sures. Pups had less ChEI than adults at comparable blood CPF levels. Oral CPFO resulted in substantial
RBC ChEI, but no brain ChEI, indicating no CPFO systemic bioavailability to peripheral tissues.
 2012 Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Chlorpyrifos (CPF) is a broad spectrum organophosphate insec-
ticide that inhibits acetylcholinesterase (AChE), which can result in
accumulation of synaptic acetylcholine, neuronal overstimulation,
and subsequently, cholinergic signs of toxicity (e.g., excessive sali-
vation, lacrimation, urination, defecation, incoordination, tremors,
etc.). Previous studies have demonstrated that young animals are
more sensitive to lethality, some neurobehavioral effects and cho-
linesterase (ChE) inhibition following acute exposures to high
doses of CPF (e.g., Pope et al., 1991). At 15–20 mg/kg, PND 17 rats
exhibited the same magnitude of brain ChE inhibition as adult rats
given 80 mg/kg CPF (Moser and Padilla, 1998; Moser et al., 1998).
Functional neurobehavioral changes following acute CPF exposure
have been correlated with ChE inhibition (Moser, 1995; Nostrandt
et al., 1997). Generally, signs of cholinergic toxicity were seen
when brain ChE was inhibited >60% (Nostrandt et al., 1997; Moser
et al., 1998). ChE inhibition is considered the most sensitive end-
point for CPF toxicity based on previous dose–response studies
and provides the most useful data for determining point ofess under CC BY-NC-ND license.departure (US EPA, 2011). These differences in sensitivity are par-
tially related to toxicokinetic differences between young animals
and adults (i.e., young animals have a lower capacity to detoxify
chlorpyrifos–oxon (CPFO), the active metabolite; Timchalk et al.,
2006).
Investigators have demonstrated that age-related differences in
sensitivity to CPF exist with acute, high-dose exposures and are
proportional to the magnitude of ChE inhibition. Pope and Chak-
raborti (1992) demonstrated that there was a high correlation be-
tween brain and plasma ChE inhibitory potency (ED50 values) and
sensitivity to acute toxicity at the maximum-tolerated dose across
age groups with acute in vivo CPF exposure. Across three organo-
phosphates (OPs), maximum-tolerated doses given to immature
and adult rats produced similar degrees of brain ChE inhibition.
With intermittent repeated exposures (i.e., 40 mg/kg CPF once
every 4 days, total of four doses), adult rats were more sensitive
to neurochemical changes, including brain ChE inhibition, than
immature rats (PND 7–20) (Chakraborti et al., 1993). The paucity
of data on age-related sensitivity at low dose levels was acknowl-
edged by the US Environmental Protection Agency (US EPA) Scien-
tiﬁc Advisory Panel (2008), which noted that there was uncertainty
regarding the relative sensitivity of young animals to ChE inhibi-
tion after exposure to low doses of CPF.
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ChE inhibition, there also were concerns for potential ChE inhibi-
tion due to exposures to CPFO. The US EPA’s Environmental Fate
and Effects Division has proposed that drinking water exposures
to CPFO are possible. Estimated drinking water concentrations
(EDWCs) of CPFO were based on Tier II surface water and Tier I
groundwater model simulations for currently registered uses of
CPF, because CPF is expected to transform to CPFO during drinking
water treatment and there are limited environmental fate data
available for CPFO, in part due to the short half-life of the oxon.
Thus, due to the concern for potential drinking water exposures,
acute and repeated-dose inhibition of ChE following CPFO expo-
sure also was examined.
This study was derived from a standard US EPA Comparative
Cholinesterase Study design to examine the relative sensitivity of
adult rats and pups to ChE inhibition with the goal to better char-
acterize age-dependent toxicity of CPF over lower portions of the
dose–response curve. These data would establish whether previ-
ously identiﬁed age-related differences in ChE inhibition at high
CPF doses apply at lower dose levels that are more relevant for hu-
man exposures. The study design also was expanded to examine
the impact of dose vehicle, dose rate, and the effect of acute and re-
peated CPFO dosing on ChE inhibition with measurements of inter-
nal dose to provide context for these results. First, immature
(postnatal day (PND) 11) and young adult rats were given acute
(single bolus) or repeated (11 day) exposures to CPF or CPFO in
corn oil. The impact of vehicle and dosing regimen was evaluated
after bolus dosing in rat milk vehicle (pups) or 12 h dietary expo-
sure (adults). The highest dose levels were selected to induce
approximately 50–60% inhibition of brain ChE in the CPF studies
and marked inhibition of RBC ChE in the CPFO studies. To examine
behavioral neurotoxicity, clinical observations were included in
the acute studies, whereas a functional observational battery
(FOB) and motor activity were included after 10 daily exposures
in the repeated dose study. Brain, RBC and plasma ChE inhibition
were measured at the time-of-peak inhibition following both acute
and repeated exposures to CPF or CPFO. Blood levels of CPF, CPFO,
and/or trichlorpyridinol (TCP) were measured to examine the rela-
tionship between ChE activity and systemic exposure levels and to
improve the existing physiologically-based pharmacokinetic/phar-
macodynamic (PBPK/PD) model for CPF (Timchalk et al., 2002,
2006). Data from this study were modeled using benchmark dose
analysis in the accompanying paper by Reiss et al. (2012).1 Laboratory fully accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC International).2. Materials and methods
2.1. Materials and animal husbandry
Chlorpyrifos Technical (CPF; O,O-diethyl O-(3,5,6-trichloro-2-
pyridinyl)ester phosphorothioic acid; 99.8% pure) and chlopyrifos–
oxon (CPFO; diethyl 3,5,6-trichloro-2-pyridinyl ester phosphoric
acid, 94.9% pure), a CPF metabolite that inhibits cholinesterase
(ChE), were supplied by Dow AgroSciences LLC (Indianapolis, Indi-
ana). Rat milk used as a vehicle in some PND 11 pup experiments
was collected fromuntreated lactating dams or was purchased from
Bioreclamation, Inc. (Hicksville, NewYork). Stability of CPF andCPFO
in corn oil andmilkwas conﬁrmedprior to the start of the pilot stud-
ies; stability of CPF in rodent diet was previously established for at
least 30 days at concentrations spanning those used in this study.
Concentration veriﬁcation and homogeneity analyses were con-
ducted for all dose solutions, and for the premix and all test diets.
Adult female Crl:CD(SD) rats were approximately 63 days of age
at receipt. Females were selected for study, because adult females
were either slightly more sensitive (e.g., Moser, 2000) or equally
sensitive to adult males (Betancourt and Carr, 2004); in otherstudies, gender-related differences were not reported (Timchalk
et al., 2006; Zheng et al., 2000). Male and female Crl:CD(SD) rat
pups were 4 or 5 days of age at the time of arrival in the laboratory.
Animals were allowed to acclimate under standard environmental
conditions for approximately one week prior to study initiation.1
Adults were singly housed and pups (8/litter) were housed with lac-
tating dams. Unless otherwise stated, LabDiet Certiﬁed Rodent Diet
#5002 (PMI Nutrition International, St. Louis, Missouri) and munici-
pal tap water were provided ad libitum and pups were given free ac-
cess to lactating dams. Adult female rats were assigned randomly to
treatment groups using a computer program designed to increase
the probability of uniform group mean weights and standard devia-
tions at the start of the study. Within litters, pups were randomly as-
signed to treatment groups with a preference for using pups of
intermediate body weights when possible (i.e., avoiding unusually
large or small pups). For all studies, pups from the same litter were
assigned to different treatment groups to control for litter effects at
each time point. The study was approved by the Institutional Animal
Care and Use Committee and complied with Good Laboratory Prac-
tice regulations.
2.2. Experimental design
The primary objective of this study was to provide data for a
comparison of CPF- and CPFO-induced ChE inhibition in pre-wean-
ling and young adult rats to determine whether age-related differ-
ences in sensitivity exist. Data were also collected to evaluate how
differences in dose vehicle (corn oil vs. milk) or dose regimen (ga-
vage vs. diet) affected the toxicokinetics and pharmacological ef-
fects of CPF. The study was conducted in four phases (Table 1):
phase 1: a range-ﬁnding study; phase 2: an acute pilot; phase 3: a
deﬁnitive acute study; and phase 4: a deﬁnitive repeat-dose study.
For each study phase, oral gavage doses were administered at a
volume of 3 ml/kg based upon body weights collected just prior to
dosing. Pups were removed from the dams approximately 1 h prior
to dosing and returned to the dams after dose administration until
the time of euthanasia. For gavage experiments, adult females
were fasted overnight prior to dose administration, then were gi-
ven ad libitum access to feed during the day. At termination, blood
and brain samples were collected at each phase for the assessment
of plasma, RBC and brain ChE levels.
2.2.1. Phase 1: range-ﬁnding study
A preliminary range-ﬁnding study was conducted to determine
the approximate dose of CPF and CPFOnecessary to producemarked
(50–60%) brain ChE inhibition in young adult female rats in order
to anchor the dose–response curves with an effective dose. For this
study, 70-day-old female rats (3/dose group) were treated as
shown in Table 1. There was a shared vehicle (corn oil) control
group. All females were weighed and dosed by gavage in the morn-
ing and ChE samples were collected at 5 h following dose adminis-
tration. Sample collection is described below.With CPFO, signiﬁcant
brain ChE inhibition was not seen, so RBC ChE inhibition was used
for CPFO dose selection in subsequent study phases (Table 2).
2.2.2. Phase 2: acute pilot study
The pilot study was conducted to determine the time-of-peak
ChE inhibition with the different dosing scenarios (Table 1). PND
11 rats (female) and young adult females (70 days of age) were
euthanized at numerous time points after administration of CPF
(3 mg/kg in PND 11 pups; 10 mg/kg in adults) or CPFO (0.5 mg/kg
in PND 11 pups; 0.3 mg/kg in adults) and ChE activity was
Table 1
Chlorpyrifos comparative cholinesterase study design.
Age Test compound Vehicle Dose level(s)a (mg/kg/day) Duration ChE sample collection timeb TK samples?
Phase 1: range-ﬁnding study
Adult (70 days of age) CPF Corn oil 0, 5, 10, 20 Single dose 5 h N
CPFO Corn oil 0, 1, 5, 10 Single dose 5 h N
Phase 2: time-of-peak inhibition study
PND 11 (F) CPF Corn oil 0, 3 Single dose 2, 4, 6, 8, 12, 24 and 48 h N
CPF Milk 0, 3 Single dose 2, 4, 6, 8, 12, 24 and 48 h N
CPFO Corn oil 0, 0.5 Single dose 2, 4, 6, 8, 12 and 24 h N
Adult (70 days of age) CPF Corn oil 0, 10 Single dose 2, 4, 6, 8, 12 and 24 h N
CPF Diet 0, 10 12-h Dietary exposure 2, 4, 6, 8, 12 and 24 h N
CPFO Corn oil 0, 0.3 Single dose 2, 4, 6, 8, 12 and 24 h N
Phase 3: acute dose–response study
PND 11 (M and F) CPF Corn oil 0, 0.05, 0.1, 0.5, 2, 5 Single dose 6 h Y
CPF Milk 0, 0.05, 0.1, 0.5, 2, 5 Single dose 8 h Y
CPFO Corn oil 0, 0.005, 0.01, 0.05, 0.1, 0.5 Single dose 4 h Y
Adult ( 70 days of age) CPF Corn oil 0, 0.05, 0.1, 0.5, 2, 10 Single dose 8 h Y
CPF Diet 0, 0.05, 0.1, 0.5, 2, 10 12-h Dietary exposure 8 h after removal of diet Y
CPFO Corn oil 0, 0.01, 0.05, 0.1, 0.5, 1 Single dose 4 h Y
Phase 4: repeat dose study
PND 11 (M and F) CPF Corn oil 0, 0.05, 0.1, 0.5, 1, 3.5 11 doses; PND 11–21 6 h Y
CPFO Corn oil 0, 0.01, 0.5 11 doses; PND 11–21 4 h Y
Adult (70 days of age) CPF Corn oil 0, 0.05, 0.1, 0.5, 1, 3.5 11 doses; 70–80 days of age 8 h Y
CPFO Corn oil 0, 0.01, 0.5 11 doses; 70–80 days of age 4 h Y
F, females; M, males.
a Whenever possible, a shared control group was used.
b Hours after administration of the last dose.
Table 2
Phase 1: range-ﬁnding study – summary of CPF and CPFO ChE inhibition in adult female CD rats after single gavage exposure in corn oil (samples collected 5 h post-exposure).
Dose group (mg/kg) RBC ChE (U/L)
(100 ll sample)
RBC ChE (U/L)
(50 ll sample)
Mean RBC ChE (U/L) Mean plasma ChE (U/L)a Brain ChE (U/L) Mean brain ChE (U/L)
0 4296 4028 4247 ± 298 2377 48,198 50,400 ± 2812
4650 4014 53,568
49,434
5 chlorpyrifos 2614 2020 2293 ± 448
(46% decrease)
737 53,505 48,840 ± 6653 (3% decrease)
2728 1808 51,794
41,222
10 chlorpyrifos 636 324 434 ± 264
(90% decrease)
433 29,675 31,400 ± 4216 (38% decrease)
112 664 28,319
36,205
20 chlorpyrifos UR UR UR 354 14,440 12,669 ± 1555 (75% decrease)
UR UR 12,038
11,529
1 chlorpyrifos–oxon 396 UR 212 (95% decrease) 633 53,257 51,422 ± 3160
28 UR 47,773
53,236
5 chlorpyrifos–oxon UR UR UR 295 52,353 51,839 ± 1221
UR UR 52,720
50,445
10 chlorpyrifos–oxon UR UR UR 362 50,331 52,183 ± 3574
UR UR 49,915
56,303
U/L, international units/L; an international enzyme unit per liter (U/L) is deﬁned as the activity of enzyme which converts 1 lmol/L of acetylthiocholine in one minute at
standard conditions.
UR, under range (lowest range of standard curve = 20).
a Hemolysis was noted in some plasma samples (subsequent procedural change made to accommodate analytical sampling).
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ChE inhibition was determined experimentally using one dose level
in the pilot study, then modeled across dose levels using the CPF
PBPK/PD model (Timchalk et al., 2002, 2006; Supplemental data 1).
2.2.3. Phase 3: deﬁnitive acute dose–response study
The experimental design for the acute study examining the
dose–response for ChE inhibition in PND 11 pups after acute CPF
or CPFO administration is outlined in Table 1. Male and female
pups (8/sex/dose; PND 11) and adult female rats (8/dose; 70 days
of age) were given a single gavage dose of 0, 0.05, 0.1, 0.5, 2, 5(pups only) or 10 (adults only) mg/kg CPF in corn oil or 0, 0.005
(pups only), 0.01, 0.05, 0.1, 0.5, or 1 (adults only) mg/kg CPFO in
corn oil. Prior to euthanasia, pups and adult female rats were given
clinical observations to determine whether signs of cholinergic
toxicity were present.
Samples (blood and brain) were collected at the time-of-peak
ChE inhibition (CPF in corn oil: 6 h post-dosing in pups and 8 h
post-dosing in adults; CPFO in corn oil: 4 h post-dosing in pups
and adults).
A separate group of PND 11 male and female pups (8/sex/dose)
were given a single gavage dose of 0, 0.05, 0.1, 0.5, 2, or 5 mg/kg
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effect of vehicle on ChE inhibition and blood levels of CPF, CPFO
and TCP. Pups were terminated at the time-of-peak ChE inhibition
(8 h after dosing as determined in the pilot study and by PBPK/PD
modeling).
A separate group of females (8/dose; 70 days of age) was ex-
posed to CPF in the diet for 12 h at concentrations designed to
achieve similar mg/kg doses to gavage CPF (0, 0.05, 0.1, 0.5, 2 or
10 mg/kg). This dosing scenario is more consistent with acute die-
tary exposures in humans and can be compared with adults ex-
posed via CPF gavage in corn oil. Females in the dietary group
were given CPF-supplemented diet at the start of the dark cycle
for 12 h, and the amount of feed consumed was measured. Females
were terminated at the time-of-peak ChE inhibition (8 h after re-
moval of the CPF-containing diets as determined in the pilot study
and by PBPK/PD modeling). Test material intake (mg/kg body
weight/day) was calculated for the 12 h dietary exposures.
2.2.4. Phase 4: deﬁnitive repeat-dose study
ChE inhibition in plasma, RBCs and brain was examined in pre-
weanling (male and female) and adult female rats after repeated
gavage exposures (11 days) to CPF or CPFO in corn oil (Table 1).
The experimental design used litters with all male or all female
pups, and assigned pups within each litter to a CPF- or CPFO-expo-
sure group. PND 11 male and female pups (8/sex/dose) and adult
female rats (8/dose) were given daily gavage doses of CPF in corn
oil at doses of 0, 0.05, 0.1, 0.5, 1, 3.5 mg/kg/day or CPFO in corn
oil at doses of 0, 0.01 or 0.5 mg/kg/day for 11 days. CPF doses were
selected to produce substantial brain ChE inhibition at the highest
dose level. CPFO, which had only two treatment groups per age,
was designed to include a high dose that caused RBC ChE inhibi-
tion, because brain inhibition was not seen with CPFO exposure.
Pups and adults received daily clinical observations on PND 11–
19 and 21 for pups and approximately 70–78 and 80 days of age
for adults. A functional observational battery (FOB) was conducted
at the approximate time-of-peak inhibition on PND 20 (prewean-
lings) or at 79 days of age (adults) to determine whether signs
of cholinergic toxicity were present. The FOB, which was con-
ducted according to previously described procedures (Mattsson
et al., 1986, 1997), included cage-side, hand-held and open-ﬁeld
observations, and measurements of body weight, rectal tempera-
ture, fore- and hindlimb grip performance, and motor activity.
The FOB was conducted by an observer who was blind to the treat-
ment status of the animal. The same observer was used for all rats.
Adult and immature rats were euthanized at 80 and 21 days of age,
respectively. Samples (blood and brain) were collected at the time-
of-peak ChE inhibition determined in the acute study (6 h and 8 h
after the last dose of CPF in pups and adults, respectively, and 4 h
after the last dose of CPFO). In addition, an aliquot of the terminal
blood sample was used to determine internal dosimetry for CPF,
CPFO and/or TCP.
2.3. Sample collection
Rats were anesthetized with isoﬂurane. Blood samples were
collected from the inferior vena cava (adults) or by heart nick with
blood collection into capillary tubes (pups). Rats were euthanized
by exsanguination followed by decapitation. An aliquot of blood
(4/dose) was analyzed for CPF, CPFO, and TCP using analytical
methods described in Brzak et al. (1998) and Mattsson et al.
(2000). Remaining blood samples were placed into heparinized
tubes and kept on ice. Brain tissue also was collected from each
rat, weighed and quick frozen in liquid nitrogen. Blood was centri-
fuged to separate plasma and packed RBCs. RBCs were diluted in 1%
Triton X-100. Samples were stored frozen (80 C) until shipped
on dry ice to WIL Research Laboratories LLC (Ashland, OH) foranalysis of ChE activity using a modiﬁed Ellman method (Ellman
et al., 1961; Hunter et al., 1997). Frozen brain samples were diluted
in 10 volumes of 1% Triton X-100 (based on brain weight), imme-
diately homogenized, centrifuged, and analyzed for ChE activity.2.4. Statistics
ChE activity was analyzed separately for adults, male and fe-
male pups to determine whether a signiﬁcant, dose-related differ-
ence in ChE inhibition exists. These analyses involved a one-way
analysis of variance (ANOVA) using dose as a factor. Descriptive
statistics (mean and standard deviation) were reported for blood
levels of CPF, CPFO and TCP. Statistical analyses were conducted
on body weights (collected at FOB time points), grip performance,
rectal temperature, motor activity and FOB observations, with
analyses being conducted separately for each age, sex and test
material. These analyses are described in Supplemental data 2.3. Results
3.1. Phase 1: range-ﬁnding study
Adult females were exposed to 0, 5, 10 or 20 mg/kg CPF or 1, 5
or 10 mg/kg CPFO to identify dose levels that produced marked
inhibition of brain ChE without maximum inhibition of RBC ChE
activity. Samples were collected at 5 h post-dosing. The high dose
level (20 mg/kg CPF) produced 75% brain ChE inhibition, with >99%
inhibition of RBC ChE activity (Table 2). At 10 mg/kg CPF, brain and
RBC ChE activity were decreased by 38% and 90%, respectively. The
highest dose of CPFO (10 mg/kg) produced >99% RBC ChE inhibi-
tion, but did not alter brain ChE activity in adult female rats. The
lowest CPFO dose (1 mg/kg) decreased RBC ChE activity by 95%.
Based on these data, 0 and 10 mg/kg CPF and 0 and 0.3 mg/kg CPFO
were selected for the time-of-peak inhibition studies in adults.
Dose levels in the time-of-peak inhibition studies in PND 11 pups
were adjusted to 0 and 3 mg/kg CPF and 0 and 0.5 mg/kg CPFO
based on the magnitude of ChE inhibition seen in adult female rats.3.2. Phase 2: time-of-peak inhibition studies
Studies were conducted to determine the time-of-peak inhibi-
tion for RBC, brain and plasma ChE in pups and adults using the dif-
ferent acute dosing scenarios. Time-of-peak inhibition for brain
ChE was used for subsequent experiments. For PND 11 pups, the
times-to-peak inhibition were 6 h post-dosing for CPF in corn oil,
4 h post-dosing for CPFO in corn oil and 8 h post-dosing for CPF
in milk. For adult female rats, the times-to peak inhibition were
8 h post-dosing for CPF in corn oil, 4 h post-dosing for CPFO in corn
oil, and 8 h post-exposure for CPF in diet (i.e., after conclusion of
the 12-h dietary exposure to CPF-containing diet). Using the
PBPK/PD model, the time-of-peak brain ChE inhibition was shown
to be similar across dose levels within each age group; therefore,
the same sample collection times could be used. The results of
the time-of-peak inhibition studies and subsequent modeling ap-
pear in Supplemental data 1.3.3. Phase 3: deﬁnitive acute dose–response study
The deﬁnitive acute comparative ChE study examined age-re-
lated differential sensitivity across multiple dose levels of CPF or
CPFO after a single exposure. Samples were collected at the time-
of-peak ChE inhibition. Blood levels of CPF, CPFO and TCP also were
determined at these time points. There were no treatment-related
clinical observations during any phase of the acute studies.
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male and female CD rat pups (8/sex/dose; 0.05–5 mg/kg sampled
6 h post-dosing) and adult female CD rats (8/dose; 0.05–10 mg/
kg sampled 8 h post-dosing) exposed to a single gavage dose of
CPF (corn oil vehicle) are shown in Table 3. At both ages, the high-
est dose level was designed to provide an anchoring point for the
dose–response curve, causing consistent, measurable brain ChE
inhibition. There were no discernable gender differences in ChE
activity in male or female PND 11 pups in response to CPF treat-
ment. At the highest dose of CPF (5 mg/kg in PND 11 pups and
10 mg/kg in adults), both pups and adults had signiﬁcant and com-
parable decreases in brain ChE activity (42.5–49% of control brain
ChE). Brain ChE was not inhibited in pups or adults at 2.0 mg/kg
CPF. Both ages also showed signiﬁcant RBC and plasma ChE inhibi-
tion at dosesP2 mg/kg. The 0.5 mg/kg CPF dose was considered a
no-observed-effect-level (NOEL) for ChE inhibition across all tis-
sues in both age groups with acute exposure.
Figs. 1A and 2A show blood levels of CPF and CPFO relative to
ChE inhibition across tissues with samples collected at the time-
of-peak ChE inhibition. Consistent with the ChE inhibition data,
there were no apparent gender-related differences in blood levels
of CPF or its metabolites in PND 11 pups; therefore, the ﬁgures
show mean pup values. In PND 11 pups, CPF and TCP were detect-
able in blood at all doses of CPF, whereas CPFO was below the level
of quantitation (LLQ) at 60.1 mg/kg CPF and only had one value
from four samples that was above the LLQ at 0.5 mg/kg CPF
(Fig. 1A). Increases in blood CPF levels were approximately dose
proportional at doses 62 mg/kg, whereas at 5 mg/kg, CPF blood
levels were 466 greater than blood levels at 0.05 mg/kg CPF with
only a 100 increase in dose. This may suggest different kinetics at
the high dose of 5 mg/kg than at lower dose levels. Furthermore,
the [TCP]:[CPF] ratio was lower at 5 mg/kg than 0.05 mg/kg (21
vs. 300, respectively), suggesting that the relative amount of CPF
metabolized to TCP is inversely related to CPF dose. This interpre-
tation is consistent with predictions by the PBPK/PD model for CPF
(Timchalk et al., 2002). In adult females, blood CPF was detectable
at doses P0.5 mg/kg and TCP was detectable at all dose levels in
adult females; whereas CPFO was at or below the LLQ at all dosesTable 3
ChE inhibition in PND 11 pups and adult females following an acute dose of CPF in corn o
Dose (mg/kg) RBC ChE (U/L) RBC ChE (% control) Brain ChE (U/L)
Adults – CPF in corn oil
0 5409 ± 351 100.0 54,728 ± 1283
0.05 5146 ± 533 95.1 54,461 ± 2301
0.1 5494 ± 357 101.6 51,116 ± 2484
0.5 5975 ± 1150 110.4 52,243 ± 1586
2.0 4360 ± 536* 80.6 52,194 ± 2580
10.0 851 ± 622* 15.7 23,276 ± 11,567*
PND 11 male pups – CPF in corn oil
0 6891 ± 782 100.0 22,765 ± 3336
0.05 7034 ± 923 102.1 25,891 ± 2664
0.1 7195 ± 861 104.4 24,339 ± 1508
0.5 6538 ± 544 94.9 25,202 ± 1847
2.0 4434 ± 590* 64.3 22,346 ± 2910
5.0 804 ± 249* 11.7 11,163 ± 2821*
PND 11 female pups – CPF in corn oil
0 6432 ± 776 100.0 24,629 ± 3768
0.05 6674 ± 634 103.8 25,125 ± 2987
0.1 6518 ± 677 101.3 24,910 ± 3080
0.5 6345 ± 1308 98.7 25,372 ± 2069
2.0 4441 ± 392* 69.0 22,933 ± 3188
5.0 873 ± 282* 13.6 10,955 ± 1517*
n = 8 pups/sex/dose level or 8 adult females/dose level unless otherwise indicated.
U/L, international units/L.
a n = 7 in the male pup plasma control group and the female pup plasma 2.0 mg/kg d
* Signiﬁcantly different from controls at alpha = 0.05 using Dunnett’s test when raw Chof CPF (Fig. 2A). It was difﬁcult to fully evaluate dose proportional-
ity (i.e., [TCP]:[CPF] ratio) in adult females with so few data points
for CPF, but TCP levels were approximately dose proportional.
When comparing TK data with ChE inhibition data, it is impor-
tant to note that samples were collected at 6 h post-dosing in PND
11 pups compared with 8 h post-dosing in adults. Furthermore, the
time-of-peak ChE inhibition may not correspond with the time-of-
peak blood levels of CPF or its metabolites, particularly given the
slow recovery of ChE activity. The peak metabolite levels may oc-
cur earlier than the sampling times chosen for ChE measurements.
However, these TK data were collected to aid in current under-
standing of metabolite ratios between dose levels, vehicle and
age. These ratios provide useful information on relative metabo-
lism of CPF between the experimental groups and are useful to re-
ﬁne PB/PK/PD models of chlorpyrifos in the adult and neonatal rat.
The TK data indicate that pups were exposed to higher blood
concentrations of CPF than adults at high doses (e.g., at 5 mg/kg,
pups had 3 higher blood CPF levels than adults given 10 mg/
kg). In addition, pups had detectable levels of CPFO at these dose
levels (5 vs. 10 mg/kg in adults), whereas pups had lower levels
of TCP (67% of adult levels at these doses). At 2 mg/kg, PND 11 pups
had 10 higher levels of blood CPF than adults; however, unlike
the proﬁle seen at the high dose, pups also had 2 higher blood
TCP levels than adults, indicating that pups were metabolizing pro-
portionately more CPF at this lower dose. There was no brain inhi-
bition in either pups or adults at 2 mg/kg CPF.
Thus, the overall proﬁle of effects was that pups were more sen-
sitive to ChE inhibition at higher doses of CPF (e.g., 5 mg/kg); how-
ever, at lower CPF levels, pups had lower ChE inhibition than adults
at comparable blood levels of CPF. There was no evidence of age-
related differential sensitivity to acute CPF exposure over the lower
portion of the dose–response curve.
(b) CPF in rat milk to PND 11 pups: data for ChE activity measured
in PND 11 male and female CD rat pups (8/sex/dose; 0.05–5 mg/kg
sampled 8 h post-dosing) exposed to a single gavage dose of CPF
(rat milk vehicle) are shown in Table 4. Similar to the experiments
using corn oil vehicle, there were no discernable gender differences
in ChE activity in male or female PND 11 pups in response to CPFil.
Brain ChE (% control) Plasma ChE (U/L) Plasma ChE (% control)
100.0 2143 ± 803 100.0
99.5 2317 ± 635 108.2
93.4 1944 ± 684 90.7
95.5 1874 ± 262 87.5
95.4 981 ± 284* 45.8
42.5 283 ± 80* 13.2
100.0 1407 ± 111a 100.0
113.7 1440 ± 221 102.3
106.9 1494 ± 177 106.2
110.7 1301 ± 89 92.4
98.2 690 ± 63* 49.0
49.0 321 ± 54* 22.8
100.0 1421 ± 106 100.0
102.0 1409 ± 150 99.1
101.1 1374 ± 200 96.7
103.0 1283 ± 136 90.3
93.1 752 ± 141*,a 53.0
44.5 313 ± 69* 22.0
ose group.
E data were analyzed (Treatment-related effects in bold text).
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Fig. 1. Mean RBC, brain and plasma ChE inhibition relative to mean blood CPF, CPFO and TCP levels in PND 11 pups following acute gavage exposure at multiple dose levels to
CPF in corn oil vehicle (A; sampled at 6 h post-dosing), milk vehicle (B; sampled at 8 h post-dosing), or CPFO in corn oil vehicle (C; sampled at 4 h post-dosing). Data show
mean values of combined male and female pup data as there were no gender-related differences in either ChE inhibition or blood CPF/CPFO levels. (n = 7–8 pups/sex/dose
level for ChE measurements; n = 4 pups/dose level for determination of blood CPF, CPFO and TCP levels).
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pups using either milk or corn oil vehicle. At 5 mg/kg CPF, brain ChE
was inhibited to approximately 47% of control in corn oil compared
with 51% of control in rat milk. As with corn oil, brain ChE was not
inhibited at 2.0 mg/kg CPF inmilk. Similarly, RBC and plasma ChE at
2.0 mg/kg CPF were inhibited to approximately 67% and 51% ofcontrol values using corn oil vehicle compared with 72% and 59%
of control values using milk vehicle. There were no signiﬁcant ef-
fects in ChE values at 0.5 mg/kg, which was the NOEL for ChE inhi-
bition across all tissues regardless of vehicle.
Fig. 1B shows blood levels of CPF and CPFO relative to ChE inhi-
bition across tissues with samples collected at the time-of-peak
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Fig. 2. Mean RBC, brain and plasma ChE inhibition relative to mean blood CPF, CPFO and TCP levels in adult female rats following acute exposure to CPF at multiple dose levels
in corn oil vehicle (gavage) (A; sampled at 8 h post-dosing), 12-h dietary exposure (B; sampled 8 h after removal of test diet), or CPFO in corn oil vehicle (gavage) (C; sampled
at 4 h post-dosing). (n = 8 rats/dose level for ChE measurements; n = 4 rats/dose level for determination of blood CPF, CPFO and TCP levels).
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no apparent gender-related differences in blood levels of CPF or itsmetabolites in PND 11 pups; therefore, the ﬁgure shows mean pup
values. At the time-of-peak inhibition, the blood CPF and CPFO
Table 4
ChE inhibition in PND 11 pups following an acute dose of CPF in rat milk.
Dose (mg/kg) RBC ChE (U/L) RBC ChE (% control) Brain ChE (U/L) Brain ChE (% control) Plasma ChE (U/L) Plasma ChE (% control)
PND 11 male pups – CPF in milk
0 6305 ± 1460 100.0 23,911 ± 1873 100.0 1613 ± 185 100.0
0.05 6017 ± 1385 95.4 24,489 ± 3432 102.4 1629 ± 181 101.0
0.1 6591 ± 924 104.5 25,279 ± 2155 105.7 1573 ± 239 97.5
0.5 6320 ± 1028 100.2 25,325 ± 2815 105.9 1510 ± 142 93.6
2.0 4459 ± 1916 70.7 24,760 ± 2744 103.6 985 ± 198⁄ 61.1
5.0 1805 ± 1706* 28.6 13,918 ± 4867* 58.2 472 ± 508* 29.2
PND 11 female pups – CPF in milk
0 6324 ± 648 100.0 26,410 ± 3026 100.0 1586 ± 137 100.0
0.05 6197 ± 614 98.0 26,113 ± 2979 98.9 1646 ± 171 103.7
0.1 6501 ± 979 102.8 26,609 ± 2104 100.8 1476 ± 179 93.0
0.5 5877 ± 1505 92.9 26,969 ± 1413 102.1 1410 ± 160 88.9
2.0 4600 ± 1759* 72.7 22,201 ± 4811 84.1 896 ± 220* 56.5
5.0 1375 ± 1634* 21.7 11,511 ± 5332* 43.6 341 ± 239* 21.5
n = 8 pups/sex/dose level.
U/L, international units/L.
* Signiﬁcantly different from controls at alpha = 0.05 using Dunnett’s test when raw ChE data were analyzed (treatment-related effects in bold text).
216 M.S. Marty et al. / Regulatory Toxicology and Pharmacology 63 (2012) 209–224levels, as well as the magnitude of ChE inhibition across tissues,
were similar with both milk and corn oil vehicles. As with CPF in
corn oil, CPF and TCP were detectable in blood at all doses of CPF
in rat milk, whereas CPFO was below the LLQ at 60.5 mg/kg CPF
(vs. the 0.1 mg/kg dose with CPF in corn oil) and only had one value
from four samples that was above the LLQ at 2.0 mg/kg CPF. In-
creases in blood CPF levels were approximately dose proportional
at doses 62 mg/kg, whereas at 5 mg/kg, CPF blood levels were
165 greater than blood levels at 0.05 mg/kg CPF with only a
100 increase in dose. This value was not as great as the 466 dif-
ferential seen with CPF in corn oil; however, there may have been
an impact of collecting samples 2 h later with CPF in milk (8 h post-
dosing vs. 6 h with corn oil). Again, these data suggest different
kinetics at the high dose of 5 mg/kg than lower dose levels, regard-
less of milk or corn oil vehicle. Furthermore, the [TCP]/[CPF] ratio
was lower at 5 mg/kg than 0.05 mg/kg (32 vs. 95, respectively),
again suggesting that the relative amount of CPF metabolized to
TCP was decreased when the CPF dose reached 5 mg/kg in milk.
This interpretation is consistent with predictions by the PBPK/PD
model for CPF.
At the time-of-peak inhibition, blood CPF and CPFO levels, as
well as the magnitude of ChE inhibition across tissues, were similar
with both milk and corn oil vehicles. Thus, PND 11 pups appeared
to be equally sensitive to ChE inhibition following acute CPF expo-
sure in either corn oil or rat milk vehicle.
(c) CPF in diet to adult females: data for ChE activity measured in
adult female rats (8/sex/dose; 0.05–10 mg/kg) exposed for 12-h to
dietary CPF are shown in Table 5. The dietary route was included as
it was considered a more relevant dosing scenario. Based on body
weights and feed consumption over the 12-h period, dietary test
material intake for these females was 0.05, 0.10, 0.53, 2.06, orTable 5
ChE inhibition in adult females following an acute 12-h exposure to CPF in the diet.
Dose (mg/kg) RBC ChE (U/L) RBC ChE (% control) Brain ChE (U/L)
Adults – CPF in diet
0 5337 ± 305 100.0 53,888 ± 1242
0.05 5164 ± 575 96.8 52,700 ± 2265
0.1 5380 ± 525 100.8 53,020 ± 1698
0.5 5219 ± 575 97.8 53,844 ± 1737
2.0 2548 ± 446* 47.7 51,294 ± 1639
10.0 167 ± 146* 3.1 41,125 ± 7650*
n = 8 adult females/dose level.
U/L = international units/L.
* Signiﬁcantly different from controls at alpha = 0.05 using Dunnett’s test when raw Ch9.59 mg/kg for the nominal doses of 0, 0.05, 0.1, 0.5, 2 or 10 mg/
kg. Samples were collected at 8 h post-dosing as determined by a
limited probe study (data in Supplemental data 1) and modeled
using the existing PBPK/PD model. Results of these experiments
are shown in Table 5. With a 12 h dietary exposure to CPF, adult
females exhibited signiﬁcant brain ChE inhibition at the same con-
centration as CPF given via gavage in corn oil (10 mg/kg); however,
the magnitude of brain ChE inhibition was less by the dietary route
(76.3% of control values compared with 42.5% of control in the oral
gavage group). Similar to corn oil gavage, brain ChE was not inhib-
ited at dietary doses 62 mg/kg CPF. Conversely, RBC ChE activity
appeared to be slightly more sensitive to dietary ChE with inhibi-
tion to 47.7% of control values at 2 mg/kg CPF (compared with
80.6% of control with gavage exposure at this dose). Again, RBC
ChE was not inhibited at dietary doses 60.5 mg/kg CPF as was seen
with gavage dosing. Plasma ChE showed a similar response to RBC
ChE activity with similar sensitivity via the dietary and gavage
routes. As with corn oil gavage, 0.5 mg/kg CPF was the NOEL for
ChE inhibition across all tissues.
Fig. 2B shows blood levels of CPF and CPFO relative to ChE inhi-
bition across tissues with samples collected at the time-of-peak
ChE inhibition. At the time-of-peak inhibition, the blood CPF and
CPFO levels, as well as the magnitude of ChE inhibition across tis-
sues, were different from the curves seen with corn oil vehicle. At
8 h post-exposure, blood CPF was >LLQ in all animals at 10 mg/kg
and in one of four animals at 2 mg/kg and CPFO was below the LLQ
in all samples, making the TK data somewhat limited for these ana-
lytes. However, TCP was detectable at all doses of CPF and in-
creased in a dose-proportional manner. With only limited
determinations, [TCP]:[CPF] ratio was similar to other dosing sce-
narios with a decrease in the proportion of CPF metabolized toBrain ChE (% control) Plasma ChE (U/L) Plasma ChE (% control)
100.0 1754 ± 395 100.0
97.8 1373 ± 249 78.3
98.4 2058 ± 458 117.3
99.9 1648 ± 364 94.0
95.2 737 ± 190* 42.0
76.3 230 ± 82* 13.1
E data were analyzed (treatment-related effects in bold text).
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TCP levels were 7.4 and 2.4 lower, respectively, by the dietary
route than via corn oil gavage. This result suggests that dose rate
impacts blood levels of CPF and its metabolites and subsequently,
the magnitude of brain ChE inhibition.
While plasma ChE was similarly inhibited by both corn oil ga-
vage and diet, RBC ChE was more inhibited by the dietary route
at 2 mg/kg (47.7% compared with 80.6% by gavage), despite having
approximately 10 and 2.3 lower blood levels of CPF and TCP,
respectively. Thus, dose rate impacts blood levels of CPF and its
metabolites and shifts the amount of ChE inhibition across tissues.
(d) CPFO in corn oil: data for ChE activity measured in PND 11
male and female CD rat pups (8/sex/dose; 0.005–1 mg/kg sampled
4 h post-dosing) and adult female CD rats (8/dose; 0.005–1 mg/kg
sampled 4 h post-dosing) exposed to a single gavage dose of CPFO
(corn oil vehicle) are shown in Table 6. At both ages, the highest
dose level was designed to provide an anchoring point for the
dose–response curve, causing consistent, measurable RBC ChE
inhibition. There were no discernable gender differences in ChE
activity in male or female PND 11 pups in response to CPFO treat-
ment. There was no signiﬁcant inhibition of brain ChE in either
pups or adults at any dose level of CPFO. This result was consistent
with results seen in the range-ﬁnding study with adult rats, in
which no brain inhibition was seen at 10 mg/kg CPFO in corn oil,
despite near complete inhibition of RBC ChE (Table 2). RBC ChE
inhibition was seen at the same dose level (0.5 mg/kg) in PND 11
pups and adults (approximately 53% and 63% of control RBC ChE
in pups and adults, respectively); however, PND 11 pups exhibited
signiﬁcant plasma ChE inhibition at a slightly lower dose than
adults (0.1 mg/kg, where pup plasma ChE was approximately
80.5% of control compared with 99% in adult females).
Figs. 1C and 2C show blood levels of CPFO relative to ChE inhi-
bition across tissues with samples collected at the time-of-peak
ChE inhibition. Consistent with the ChE inhibition data, there were
no apparent gender-related differences in blood levels of CPFO in
PND 11 pups; therefore, the ﬁgures show mean pup values. Plasma
ChE inhibition in pups at 0.1 mg/kg CPFO may be related to higher
CPFO blood levels as suggested by the 1.6 higher blood TCP levels
in pups at this dose level (CPFO was below the LLQ in pups andTable 6
ChE inhibition in PND 11 pups and adult females following an acute dose of CPFO in corn
Dose (mg/kg) RBC ChE (U/L) RBC ChE (% control) Brain ChE (U/L)
Adults – CPFO in corn oil
0 5630 ± 906 100.0 52,826 ± 2036
0.01 5510 ± 662 97.9 52,517 ± 1503
0.05 5830 ± 402 103.5 53,203 ± 2367
0.1 5655 ± 210 100.4 51,751 ± 991
0.5 3572 ± 905* 63.4 51,169 ± 1299
1.0 1338 ± 497* 23.8 51,046 ± 1830
PND 11 male pups – CPFO in corn oil
0 6564 ± 513 100.0 25,539 ± 1711
0.005 6174 ± 828 94.1 24,558 ± 2114
0.01 5565 ± 1281 84.8 23,709 ± 2580
0.05 6159 ± 807 93.8 24,800 ± 3116
0.1 5506 ± 977 83.9 24,798 ± 2812
0.5 3534 ± 489* 53.8 23,489 ± 3133
PND 11 female pups – CPFO in corn oil
0 6287 ± 856 100.0 22,994 ± 4168
0.005 6146 ± 1557 97.7 22,436 ± 1790
0.01 6227 ± 1234 99.0 22,358 ± 2620
0.05 5444 ± 1025 86.6 24,178 ± 1236
0.1 5651 ± 1274 89.9 22,202 ± 3687
0.5 3329 ± 772* 52.9 22,462 ± 2964
n = 8 pups/sex/dose level or 8 adult females/dose level.
U/L, international units/L.
* Signiﬁcantly different from controls at alpha = 0.05 using Dunnett’s test when raw Chadults). In adults, CPFO was below the LLQ at all dose levels,
whereas TCP was detectable at all doses of CPFO. In both pups
and adults, blood TCP levels increased in a dose-related fashion,
although the increase was lower than dose proportional in PND
11 pups at CPFO doses P0.05 mg/kg (i.e., with a 100 increase
in CPFO dose from 0.005 to 0.5 mg/kg, TCP levels increased only
23) and at or slightly greater than dose proportional in adults.
With samples collected at the same time post-dosing (4 h), pups
and adults had similar levels of ChE inhibition in RBCs and plasma
at 0.5 mg/kg CPFO, although pups had 1.7 higher levels of blood
TCP. At 0.1 mg/kg CPFO, neither pups nor adults had signiﬁcant
inhibition of RBC ChE, but pups had signiﬁcant inhibition of plasma
ChE. Pup blood TCP was again 1.6 higher than blood TCP levels in
adults; thus, it was possible that higher CPFO dosimetry in pups
explained this difference. At 0.05 mg/kg CPFO, pups had similar
levels of TCP as adults at 0.1 mg/kg CPFO. At this internal dose,
there was no inhibition of ChE in any tissue. Brain ChE was not
inhibited at any dose of CPFO in either pups or adults when the
highest oxon dose (0.5 mg/kg) yielded TCP levels of 387.5 ng/g
and 724.8 ng/g, respectively.
Thus, the 0.1 mg/kg CPFO dose was considered a NOEL for ChE
inhibition in RBC in PND 11 pups and a NOEL in both RBC and plas-
ma for adult females with acute exposure. Due to plasma ChE inhi-
bition at 0.1 mg/kg CPFO, 0.05 mg/kg CPFO was the NOEL across all
tissues in PND 11 pups with acute CPFO exposure.
3.4. Phase 4: deﬁnitive repeat-dose study
The deﬁnitive repeat-dose study examined age-related differen-
tial sensitivity across multiple dose levels of CPF or CPFO after 11
daily doses administered by gavage. Blood levels of CPF, CPFO
and TCP also were determined in terminal samples collected at
the time-of-peak inhibition determined in the acute studies.
(a) CPF in corn oil: in the repeated dose study, there were no
treatment-related clinical observations in male or female rat pups
(8/sex/dose; dosed PND 11–21) or adult female rats (8/dose; dosed
PND 70–80) following exposure to eleven daily gavage doses (corn
oil vehicle) of 0, 0.05, 0.1, 0.5, 1, or 3.5 mg/kg/day CPF (data not
shown). Neither pup nor adult female body weights were affectedoil.
Brain ChE (% control) Plasma ChE (U/L) Plasma ChE (% control)
100.0 2106 ± 562 100.0
99.4 1922 ± 369 91.3
100.7 1984 ± 374 94.2
98.0 2088 ± 736 99.2
96.9 931 ± 369* 44.2
96.6 502 ± 141* 23.8
100.0 1445 ± 118 100.0
96.2 1362 ± 115 94.2
92.8 1466 ± 127 101.4
97.1 1378 ± 210 95.4
97.1 1182 ± 190* 81.8
92.0 738 ± 72* 51.1
100.0 1487 ± 210 100.0
97.6 1428 ± 125 96.0
97.2 1433 ± 172 96.4
105.2 1352 ± 200 90.9
96.6 1179 ± 124* 79.3
97.7 723 ± 62* 48.6
E data were analyzed (treatment-related effects in bold text).
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weights in Supplemental data 2). There were no treatment-related
effects on neurobehavioral endpoints, which included a FOB and
motor activity, evaluated at the time-of-peak ChE inhibition after
the 10th dose of CPF (Supplemental data 2).
Data for ChE activity measured in PND 21 male and female rat
pups and 80-day-old female rats exposed to various doses of CPF
for eleven days are shown in Table 7. At both ages, the highest dose
levels were designed to provide an anchoring point for the dose–
response curves, causing consistent, measurable brain ChE inhibi-
tion. Samples for ChE inhibition were collected at the time-of-peak
inhibition determined in the acute studies – 6 h post-dosing for the
pups and 8 h post-dosing in the adults. At the high dose of CPF
(3.5 mg/kg/day), pups had similar ChE inhibition to adults across
all tissues. At 1 mg/kg/day, ChE was signiﬁcantly decreased in both
pups and adults across all tissues, although adult brain ChE activity
was 91.1% of control, a change that was not considered biologically
meaningful. At 0.5 mg/kg/day, there was no signiﬁcant brain ChE
inhibition in either adults or pups, but both age groups had signif-
icant decreases in RBC ChE activity and plasma ChE activity with
no apparent difference in sensitivity. RBC ChE was signiﬁcantly de-
creased in adults at 0.1 mg/kg/day, but this result was considered
spurious because plasma ChE, which has similar or greater sensi-
tivity to ChE inhibition by CPF (Lotti, 1995; Garabrant et al.,
2009; UE EPA, 2008; Timchalk et al., 2006) was not inhibited at this
dose. Thus, for a given CPF dose level, pups were equally sensitive
to plasma ChE inhibition as adults. The 0.1 mg/kg/day CPF dose
was considered a no-observed-effect-level (NOEL) for ChE inhibi-
tion across all tissues in both age groups with repeated exposure.
Fig. 3 shows blood levels of CPF and CPFO relative to ChE inhi-
bition across tissues with samples collected at the time-of-peak
ChE inhibition as determined in the acute CPF experiments. In
PND 21 pups, CPF and TCP were detected in blood at all doses of
CPF, whereas CPFO was below the LLQ (Fig. 3A). Overall, there were
dose proportional increases in blood CPF and TCP levels; that is, as
the doses increased from 0.05 to 3.5 (70 from low to high dose),
blood CPF and TCP levels increased approximately 74 and 82,Table 7
ChE Inhibition in PND 21 pups and adult (PND 80) females following repeated doses of
Dose (mg/kg/day) RBC ChE (U/L) RBC ChE (% Control) Brain ChE (U/L)
Adults – CPF in corn oil
0 4903 ± 276 100.0 51,978 ± 1803
0.05 4655 ± 713a 94.9 51,929 ± 1031a
0.1 4120 ± 489* 84.0 51,990 ± 3291
0.5 3946 ± 722* 80.5 51,694 ± 1862
1.0 1335 ± 395* 27.2 47,357 ± 1938*
3.5 135 ± 185* 2.7 16,093 ± 2362*
PND 21 male pups – CPF in corn oil
0 6410 ± 1605 100.0 43,265 ± 1500
0.05 5517 ± 1180 86.1 43,558 ± 1981
0.1 5450 ± 1294 85.0 42,657 ± 1576
0.5 4054 ± 1112* 63.2 40,780 ± 1865
1.0 2478 ± 533* 38.7 31,006 ± 4154*
3.5 540 ± 332* 8.4 13,898 ± 988*
PND 21 female pups – CPF in corn oil
0 5951 ± 2082 100.0 42,289 ± 1616
0.05 6388 ± 1021 107.3 44,726 ± 2598
0.1 5882 ± 1282 98.8 43,499 ± 1409
0.5 4870 ± 829 81.8 42,810 ± 1258
1.0 3333 ± 821* 56.0 34,266 ± 2009*
3.5 723 ± 264* 12.1 17,344 ± 2414*
n = 8 pups/sex/dose level or 8 adult females/dose level unless otherwise indicated.
U/L, international units/L.
a n = 7 adult females in the 0.05 mg/kg/day dose group.
* Signiﬁcantly different from controls at alpha = 0.05 using Dunnett’s test when raw Chrespectively. There was no consistent pattern in the ratio of blood
[TCP]:[CPF] across dose groups. For adults, CPF was detected in
blood samples at doses P0.5 mg/kg/day CPF, whereas CPFO was
below the LLQ at all doses (Fig. 3B). TCP was detected in blood at
all dose levels. There was a dose proportional increase in blood
TCP levels; that is, as the doses increased from 0.05 to 3.5 (70
from low to high dose), blood TCP levels increased 78. With lim-
ited data on CPF levels in blood, a pattern in the ratio of blood
[TCP]:[CPF] could not be evaluated.
Blood levels of CPF and its metabolites facilitated interpretation
of repeat-dose data. For example, at 0.5–1.0 mg/kg/day CPF, male
pup RBC ChE was 63.2% and 38.7% of control compared with
81.8% and 56.0% of control in female pups at these dose levels.
Based on blood values, there were no clear gender-related differ-
ences in CPF and TCP levels to support a differential sensitivity of
male vs. female RBC ChE activity. Furthermore, plasma ChE inhibi-
tion was similar in both sexes at these doses. Therefore, it was con-
cluded that this apparent gender-related difference in RBC ChE
sensitivity was spurious. Gender-related differences in sensitivity
were not seen in preweanling rats in other CPF studies (e.g., Moser
and Padilla, 1998). As with the acute studies, pups had lower ChE
inhibition across tissues at comparable CPF blood levels (e.g.,
approximately 27% RBC and plasma ChE inhibition and 2% brain
ChE inhibition with CPF blood levels of 0.60 ng/g in pups compared
with 71% RBC and plasma ChE inhibition and 9% brain ChE inhibi-
tion with 0.54 ng/g blood CPF in adults). The later sampling time in
adults (8 h vs. 6 h in pups), coupled with a somewhat higher met-
abolic rate in adults, may have resulted in comparable blood levels.
At 1 mg/kg/day, it appeared that RBC and plasma were less affected
in pups, whereas brain was more affected; however, the magnitude
of the brain ChE inhibition in pups was consistent with other brain
ChE results for these blood CPF levels (i.e., mean pup blood CPF was
1.69 ng/g with 76% of control brain ChE activity; these values were
between the blood CPF levels (0.54 and 2.21 ng/g, respectively) and
brain ChE activity (91.1 and 31% of control, respectively) in adults
given 1 or 3.5 mg/kg/day CPF, respectively). At 0.5 mg/kg/day,
there was no signiﬁcant brain ChE inhibition in either adults orCPF in corn oil.
Brain ChE (% Control) Plasma ChE (U/L) Plasma ChE (% Control)
100.0 2254 ± 744 100.0
99.9 2892 ± 1052a 128.3
100.0 2617 ± 770 116.1
99.5 1220 ± 562* 54.1
91.1 691 ± 316* 30.7
31.0 262 ± 73* 11.6
100.0 903 ± 111 100.0
100.7 949 ± 148 104.9
98.6 902 ± 136 99.6
94.3 645 ± 58* 71.3
71.7 508 ± 70* 56.5
32.1 187 ± 22* 20.8
100.0 928 ± 122 100.0
105.8 921 ± 45 99.2
102.9 864 ± 95 93.1
101.2 713 ± 173* 76.8
81.0 519 ± 64* 55.9
41.0 266 ± 51* 28.7
E data were analyzed (treatment-related effects in bold text).
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Fig. 3. Mean RBC, brain and plasma ChE inhibition relative to mean blood CPF, CPFO and TCP levels in PND 21 pups (A; sampled at 6 h after the last dose) or adult female rats
(B; sampled at 8 h after the last dose) following daily gavage dosing with CPF in corn oil vehicle at multiple dose levels for 11 days. Data show mean values of combined male
and female pup data as there were no gender-related differences in either ChE inhibition or blood CPF/CPFO levels. (n = 8 pups/sex/dose level or 7–8 adult females/dose level
for ChE measurements; n = 4 pups or 4 adults in each dose group for determination of blood CPF, CPFO and TCP levels except for 3 pups in the control group and 3 adults in the
0.05 mg/kg/day group).
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ChE activity with no apparent difference in sensitivity, despite a
4.6 higher blood CPF level in pups. Interestingly, the pup blood
CPF level at 0.5 mg/kg/day was similar to blood levels in adults gi-
ven 1 mg/kg/day CPF, a dose at which signiﬁcant ChE inhibition
was seen in all tissues in the adults. Thus, for a given blood CPF le-
vel, pups were equally or less sensitive to ChE inhibition as adults.
As chlorpyrifos doses decrease below 1 mg/kg/day, there was no
evidence of increased sensitivity in pups to CPF-induced ChE inhi-
bition. At 0.1 mg/kg/day, CPF and CPFO were below the LLQ and
TCP values were similar in adults and pups at 0.1 mg/kg/day, sup-
porting the concept that pups would not be more sensitive to CPF
at lower dose levels.
(b) CPFO in corn oil: in the repeat dose study, there were no
treatment-related clinical observations in male or female rat pups
(8/sex/dose; dosed PND 11–21) or adult female rats (8/dose; dosed
PND 70–80) following exposure to eleven daily gavage doses of 0
(corn oil vehicle), 0.01 or 0.5 mg/kg/day CPFO (data not shown).
There were no treatment-related effects on body weight and nei-
ther pups nor adult females exhibited effects on neurobehavioral
endpoints (i.e., FOB and motor activity; Supplemental data 2) eval-
uated at the time-of-peak ChE inhibition after the 10th CPFO dose
(i.e., 4 h post-dosing; Supplemental data 1).Data for ChE activity measured in PND 21 male and female rat
pups and 80-day-old female rats exposed to various doses of CPFO
for eleven days are shown in Table 8. Once again, the high dose was
selected to provide consistent, measurable RBC and plasma ChE
inhibition. Samples for ChE inhibition were collected at the time-
of-peak ChE inhibition determined in the acute studies. In response
to repeated CPFO treatment, there was no discernable gender or
age-related difference in ChE activity in male or female PND 21
pups or PND 80 adult females. There was no signiﬁcant inhibition
of brain ChE at any doses of CPFO (60.5 mg/kg/day) in either pups
or adults. The magnitude of RBC and plasma ChE in pups and adults
was similar at 0.5 mg/kg/day CPFO, although adults had 2 the lev-
els of TCP as pups. ChE was not inhibited in either of these tissues
at 0.01 mg/kg/day in either adults or pups.
Fig. 4 shows blood levels of CPFO relative to ChE inhibition
across tissues with samples collected at 4 h post-dosing. In both
pups and adults, TCP was detectable in blood at all doses of CPFO
(including two PND 21 control samples, which reﬂected some var-
iability in detection around the LLQ; data not shown). TCP levels
were increased in a dose-related fashion, although the increase
was lower than dose proportional in pups (i.e., with a 50 increase
in CPFO dose (0.01 to 0.5 mg/kg/day), TCP levels increased only
20) vs. approximately dose proportional in adults (i.e., with a
Table 8
ChE inhibition in PND 21 pups and adult (PND 80) females following repeated doses of CPFO in corn oil.
Dose (mg/kg/day) RBC ChE (U/L) RBC ChE (% control) Brain ChE (U/L) Brain ChE (% control) Plasma ChE (U/L) Plasma ChE (% control)
Adults – CPFO in corn oil
0 4903 ± 276 100.0 51,978 ± 1803 100.0 2254 ± 744 100.0
0.01 5227 ± 1065 106.6 51,480 ± 1954 99.0 2814 ± 1122 124.8
0.5 619 ± 228* 12.6 51,161 ± 2204 98.4 541 ± 160* 24.0
PND 21 male pups – CPFO in corn oil
0 6410 ± 1605 100.0 43,265 ± 1500 100.0 905 ± 111 100.0
0.01 5849 ± 1153 91.2 43,429 ± 1395 100.4 933 ± 136 103.9
0.5 1013 ± 537*,a 15.8 43,003 ± 1747a 99.4 344 ± 51*,a 38.3
PND 21 female pups – CPFO in corn oil
0 5951 ± 2082 100.0 42,289 ± 1616 100.0 928 ± 122 100.0
0.01 5163 ± 1199 86.8 44,273 ± 1639 104.7 903 ± 95 97.2
0.5 813 ± 304* 13.7 38,762 ± 12,286 91.7 362 ± 34* 39.0
n = 8 pups/sex/dose level or 8 adult females/dose level unless otherwise indicated.
U/L, international units/L.
a n = 7 male pups in the 0.5 mg/kg/day dose group
* Signiﬁcantly different from controls at alpha = 0.05 using Dunnett’s test when raw ChE data were analyzed (treatment-related effects in bold text).
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Fig. 4. Mean RBC, brain and plasma ChE inhibition relative to mean blood CPFO and TCP levels in PND 21 pups (A; sampled 4 h after the last dose) or adult female rats (B;
sampled 4 h after the last dose) following daily gavage dosing with CPFO in corn oil vehicle at two dose levels for 11 days. Data show mean values of combined male and
female pup data as there were no gender-related differences in either ChE inhibition or blood CPFO levels. (n = 7–8 pups/sex/dose level or 8 adult females/dose level for ChE
measurements; n = 4 pups or 4 adults in each dose group for determination of blood CPFO and TCP levels except for 3 pups in the control group).
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had higher levels of TCP than pups at 0.5 mg/kg/day CPFO, whereaspups had 1.5 TCP blood levels compared with adults at the lower
dose level of CPFO.
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thus, the 0.01 mg/kg/day CPFO dose was considered a no-ob-
served-effect-level (NOEL) for ChE inhibition across all tissues in
both age groups with repeated exposure.4. Discussion
This comparative cholinesterase study was designed to examine
whether there were age-related differences in sensitivity to ChE
inhibition following CPF exposure. The effects of acute CPF expo-
sure in PND 11 pups compared with adults showed that there were
dose-dependent differences in sensitivity at high doses (i.e., 5 mg/
kg in corn oil), where pups were more sensitive than adults. At
lower dose levels, pups and adults showed signiﬁcant plasma
and RBC or brain ChE inhibition at the same dose levels. When
using rat milk as an alternate vehicle to simulate lactational expo-
sures, ChE inhibition in PND 11 pups was similar to levels achieved
when administering CPF in corn oil. In adults, acute CPF exposure
by gavage (corn oil vehicle) or using a alternate dosing scenario
(i.e., 12-h dietary exposure in adult females) showed that dose rate
affects the relative magnitude of ChE inhibition across tissues, be-
cause ChE inhibition was greater in RBC, but less in brain, with die-
tary exposures. With 11 daily exposures to CPF (corn oil vehicle),
both pups and adults showed similar sensitivity to ChE inhibition
across tissues. Brain ChE was not inhibited in either adults or pups
at any dose of CPFO tested, despite similar sensitivity at ages to
CPFO inhibition of RBC and plasma ChE. Together, these data indi-
cate that young animals are not more sensitive than adults to CPF-
or CPFO-induced ChE inhibition across the lower portion of the
dose–response curves.
PND 11 pups were selected as the comparison group for adult fe-
males in this study based on EPA guidance for comparative cholines-
terase studies. Across species, brain development follows
predetermined developmental patterns; however, the timing of
these developmental stages relative to birth varies. Consequently,
the degree of functional maturity of the nervous system also varies
at birth. There is ample data to support the concept that compared
to humans, rats are altricial (i.e., born less mature) with respect to
neurodevelopment. Usingmorphometricmeasurements and neuro-
genesis in different brain regions, Bayer et al. (1993) concluded that
the full-term human brain at birth was approximately equal to a
PND 14–21 rat brain. Similar conclusions also have been expressed
by others (Vidair, 2004; Clancy et al., 2007). Data suggest that the
blood–brain barrier (BBB) in humans ismore developed at birth than
the BBB in neonatal rats (Adinolﬁ and Haddad, 1977; Bonati et al.,
1981). Thus, PND 11 rat pups represent an appropriately conserva-
tive model to examine potential effects in human infants.
When examining control animals from the acute phase of the
comparative ChE study, adults had greater brain and plasma ChE
activity, whereas pups had greater RBC ChE activity. In the re-
peat-dose study, when pups were euthanized on PND 21, brain
ChE activity in the control group was approximately 80% higher
than levels in PND 11 control pups. This was consistent with pre-
vious reports (Moser et al., 1998; Timchalk et al., 2006) that have
demonstrated increases in brain ChE as rats mature. There was
no apparent maturational pattern for RBC and plasma ChE activity,
which were approximately similar at both PND 11 and 21. Tim-
chalk et al. (2006) reported that RBC ChE enzyme activity increased
between PND 5 and 12, then decreased slightly on PND 17,
whereas plasma ChE activity was relatively stable across ages.
With acute exposures in corn oil, the relative sensitivity of
adults compared with pups was dose dependent. At high dose lev-
els, PND 11 pups were more sensitive to CPF-induced ChE inhibi-
tion because 5 mg/kg CPF induced similar levels of plasma, RBC
and brain ChE inhibition as 10 mg/kg in adults. However, at lowerdoses of CPF, the dose–response curves for adults and immature
rats intersected (see Figure S-21; Supplemental data 1), such that
2 mg/kg did not cause signiﬁcant brain ChE inhibition in either
adults or pups, but caused signiﬁcant RBC and plasma ChE in both
age groups. As reported previously (US EPA, 2011), signiﬁcant RBC
and plasma ChE inhibition occurred at lower dose levels than brain
ChE inhibition in both PND 11 pups and adults. The NOEL for ChE
inhibition across all tissues (0.5 mg/kg) was the same for both
adults and pups. There was no signiﬁcant difference in sensitivity
to ChE inhibition between male and female PND 11 pups, consis-
tent with other reports in preweanling animals (e.g., Moser and
Padilla, 1998; Moser et al., 1998). Thus, at lower doses, adult fe-
male rats and PND 11 rat pups exhibited similar sensitivity across
all tissues, although pups had higher blood levels of CPF at all dose
levels.
The enhanced sensitivity of pups to acute CPF exposure at high-
er dose levels has been reported previously (e.g., Moser et al., 1998
at doses >5 mg/kg) and was partially attributed to the lower met-
abolic capacity in younger animals (Timchalk et al., 2006). There is
evidence that pups metabolize high doses of CPF more slowly than
adults. When examining [TCP]/[CPF] ratios across studies, which is
an indicator of metabolic capacity of an animal, it appears that this
ratio is 50 in PND 5 pups at 6 h after dosing 1 mg/kg CPF in corn
oil (Marty et al., 2007), 102–170 in PND 11 pups at 6 h after dosing
with 0.5–2 mg/kg CPF in corn oil and 449–810 in adult females at
8 h after dosing 0.5–2 mg/kg CPF in corn oil. These data show
greater metabolic capacity was present in adults; however, TCP
formation was favored in the older age groups as blood TCP con-
centrations exceeded parent CPF by a factor of 100-fold or greater
by PND 11, consistent with the ﬁndings of Timchalk et al. (2006).
The production of CPFO depends on the rate of hepatic activation
of CPF and inactivation of CPFO by cytochrome P450monooxygena-
ses (Ma and Chambers, 1994; Sultatos, 1994; Sultatos et al., 1984).
CPF is extensively metabolized into water soluble metabolites,
which prevents the accumulation of CPF or its metabolites (US
EPA, 2011). Other pathways involved in CPFO inactivation include
interactions with esterases other than AChE (e.g., butyrylcholines-
terases, which is hypothesized to scavenge CPFO to prevents its
interaction with peripheral target sites; Maxwell 1992a,b; US
EPA, 2011) or binding to B-esterases (e.g., carboxylesterases), both
of which decrease the amount of CPFO available to interact with
the target site (AChE). In addition, hydrolysis of the oxon by A-
esterases (i.e., PON-1; CPF-oxonase; Behnke and Murphy, 1975;
Costa et al., 1990) leads to the formation of TCP and diethylphos-
phate, which do not inhibit AChE. Data indicate that these detoxiﬁ-
cation pathways continue to mature postnatally in rats and the
maturation of these systems parallels decreases in sensitivity to
high-dose, acute CPF exposure (Mortensen et al., 1996; Atterberry
et al., 1997; Maxwell, 1992a,b; Chand et al., 1997; Morgan et al.,
1994). Moser et al. (1998) showed that preweanling rats have lower
levels of both liver and plasma carboxylesterases and A-esterase
activity than adults, which correlates with the gradual decrease in
sensitivity as rats mature. However, in humans, available data indi-
cate that liver carboxylesterase activity does not differ between in-
fants and adults as activity appears to change relatively little during
postnatal maturation (Pope et al., 2005). Furthermore, Smith et al.
(2011) found no age-related differences in CPF metabolism
in vitro using hepatic microsomes isolated from humans at 13 days
to 75 years old, whereas age-dependent increases in CPFO esterase
metabolism in human plasma (3 days to 46 years) were reported.
Levels of ChE inhibition following acute ChE exposure in the
current study were generally consistent with previously published
studies in immature animals, although this study included multi-
ple dose levels at the lower portion of the dose response curve
(i.e., <1 mg/kg). In the study by Timchalk et al. (2006), RBC and
plasma inhibition were seen in PND 5 and 12 pups at 1 mg/kg
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inhibition was seen in these tissues at 2 mg/kg, but was not seen
at 0.5 mg/kg in PND 11 pups. Zheng et al. (2000) reported a de-
crease in plasma and RBC ChE at doses of 0.45 and 1.5 mg/kg
CPF, respectively, in PND 7 pups. The reason for this difference in
plasma ChE inhibition may be related to differences in study de-
signs, sampling times, or ages of the pups from which ChE activity
was measured. In the current study, there were no effects on brain
ChE activity at 2 mg/kg on PND 11, which was consistent with Tim-
chalk et al. (2006), who reported no effects on brain ChE activity at
1 mg/kg in PND 12 pups. Overall, when considering dose and pup
age, the levels of ChE inhibition across tissues in this study were
consistent with the existing scientiﬁc literature.
The variability in ChE measurements in the current study were
consistent with variability reported in other studies, giving the cur-
rent study a similar level of sensitivity to previous work. Coefﬁ-
cients of variation (CVs) for control ChE values appear in
Supplemental data 3. In the acute dose–response studies (n = 8/
sex/dose for pups or n = 8/dose for adult females), RBC CVs ranged
from 6.5% to 23.2%, brain CVs ranged from 2.3% to 18.1% and plas-
ma CVs ranged from 7.5% to 37.5%. In the repeat dose studies
(n = 8/sex/dose for pups or n = 8/dose for adult females), RBC CVs
ranged from 5.6% to 35.0%, brain CVs ranged from 3.5% to 3.8%
and plasma CVs ranged from 12.3% to 33.0%. These results were
consistent with expectations as brain ChE activity was the least
variable of the tissues measured, whereas there was more variabil-
ity in plasma ChE, which contains mixed activity (i.e., butyryl- and
acetyl-cholinesterase). A CV comparison for treated animals was
not included as variance was expected to be higher in treated ani-
mals due to inter-animal differences, including differences in
absorption, distribution, metabolism, and excretion, individual dif-
ferences in response to treatment (particularly in steeper portions
of the dose–response curve), slight differences in dose delivered,
etc. The similarity in CVs to other published studies shows that
these assays were reasonably sensitive to detect changes in ChE
activity when such changes were present.
When using rat milk as an alternative vehicle in PND 11 pups to
simulate lactational exposures, ChE inhibition was similar to levels
achieved when administering CPF in corn oil. At the time-of-peak
inhibition, blood CPF and CPFO levels, as well as the magnitude of
ChE inhibition across tissues, were similar with both milk and corn
oil vehicles (Fig. 1A and B). This was unexpected as kinetic data for
blood CPF and blood TCP in PND 5 pups (1 mg/kg CPF in corn oil or
in milk) showed a similar time to maximal concentration (Cmax) for
both oil and milk vehicles with a notable increase in blood CPF Cmax
in pups dosed with corn oil (Marty et al., 2007). Based on the estab-
lished PBPK/PDmodel for CPF in immature rat pups (Timchalk et al.,
2002, 2006), the peak for pup blood levels of CPF after administra-
tion in rat milk was 5–7 h. Given the slow recovery of ChE activity,
the ChE inhibition was comparable even with different time points
examined (6 vs. 8 h post-dosing). In their recent assessment, the US
EPA determined that RBC ChE inhibition in PND 11 pups exposed
acutely to CPF in milk had the lowest oral point of departure in
the CPF database (US EPA, 2011).
When using an acute 12-h dietary exposure in adults to simu-
late CPF exposures in the diet over a day, dose rate apparently im-
pacted the relative magnitude of tissue ChE inhibition. The slower
dose rate likely allowed more time for detoxiﬁcation pathways,
such that less CPF was available to interact with brain ChE. Data
from these studies have shown that CPFO at <10 mg/kg did not in-
hibit brain ChE activity in adult females. Therefore, it is possible
that the slower dose rate allowed greater opportunity for P450
metabolism and/or interaction of CPFO with carboxylesterases or
other ChEs (e.g., butyrylcholinesterase) so that less CPFO was avail-
able to interact with brain ChE. Timchalk et al. (2006) reported that
differences in tissue dosimetry (higher oxon AUC in blood relativeto brain) contribute to enhanced sensitivity of blood relative to
brain ChE. This seems plausible as RBC ChE showed greater inhibi-
tion with dietary CPF dosing, although plasma ChE inhibition was
the same with both gavage and dietary treatment.
In the current study, there were no signs of cholinergic toxicity
detected in either the acute study (clinical observations at 65 mg/
kg in pups or 610 mg/kg in adults) or the repeat-dose study (clin-
ical observations and FOB with motor activity at 63.5 mg/kg/day
in both age groups), despite signiﬁcant brain ChE inhibition
(53–58% in the acute study and 59–69% in the repeat dose study).
Moser (2000) reported that PND 17 female rats had a decrease in
tail-pinch response at 6.5 h post-dosing with 4 mg/kg CPF, whereas
males were not affected at this dose level. At a higher CPF dose
(i.e.,10 mg/kg) than those given to pups in the current study, Moser
(2000) observed alterations in numerous neurobehavioral end-
points in both male and female PND 17 pups including altered
gait/ataxia, decreased arousal state, tail-pinch response (males),
tremors, smacking (males) and lacrimation (females). In adults, de-
creased motor activity (total counts) was the most sensitive end-
point with decreases in males noted at 3.5 h post-dosing with
10 mg/kg, whereas both males and females were affected at
50 mg/kg, along with other cholinergic signs of toxicity (Moser,
2000). In a separate study (Moser et al., 1998), PND 17 female rats
with a 50–60% decrease in brain ChE activity following acute expo-
sure to 5 mg/kg CPF showed decreased open-ﬁeld arousal, and in
adult males, there was a correlation between a 40–50% decrease
in brain ChE activity and decreased motor activity at 20 mg/kg
CPF. Numerous factors may have contributed to differences in neu-
robehavioral effects in the previous studies by Moser et al. and the
current study, including differences in dose levels (generally lower
in the present study), developmental stage, neurobehavioral meth-
ods, or possibly receptor down regulation, which has been pro-
posed to account for recovery of neurobehavioral performance
(Bignami et al., 1975; Nostrandt et al., 1997; Moser and Padilla,
1998). Perhaps the gender-related differences in sensitivity to neu-
robehavioral effects in the Moser studies, in the presence of similar
brain ChE inhibition in both sexes, indicate that these effects oc-
curred near the threshold for neurobehavioral alterations, which
could vary slightly across studies.
With repeated exposures, adults and PND 11 pups were similar
in sensitivity to ChE inhibition by CPF. Signiﬁcant brain ChE inhibi-
tion was seen in both adults and pups at 1.0 mg/kg/day CPF,
whereas signiﬁcant plasma and RBC inhibition occurred in both
age groups at 0.5 mg/kg/day. In 2008, the US EPA Science Advisory
Panel (2008) hypothesized that young animals might be less sensi-
tive to repeated CPF exposure due to decreased levels of enzymes
converting CPF to CPFO and/or a more rapid increase in AChE activ-
ity in tissues of young animals, likely due to increased rates of pro-
tein synthesis (e.g., Chakraborti et al., 1993; Liu et al., 1999). The
current study veriﬁed that pups achieve higher blood levels of
CPF for a given dose, presumably due to slower metabolism to
TCP. Based on administered dose, these immature animals showed
similar sensitivity to CPF-induced ChE inhibition as adults; how-
ever, based on blood levels, pups showed lower sensitivity to
CPF-induced ChE inhibition. A recent physiologically based phar-
macokinetic/pharmacodynamic (PBPK/PD) model using human
CYP-speciﬁc kinetic parameters and age-based differences in hepa-
tic CYP content predicted that 1 year-olds would be less sensitive
than 19-year olds to CPF-induced butyryl- and acetyl-ChE inhibi-
tion, although age-related differences in PON-1 levels and micro-
somal liver content are needed to reﬁne the model (Foxenberg
et al., 2011).
In adult females, there was signiﬁcant inhibition of RBC ChE
activity at 0.1 mg/kg/day in the repeat-dose study, which was
deemed incidental as plasma ChE was not signiﬁcantly altered at
this dose level. Plasma ChE has similar or greater sensitivity than
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EPA, 2008). Plasma ChE, which is comprised of half butyrylcholin-
esterase and half AChE (Timchalk et al., 2006), is more readily
inhibited because butyrylcholinesterase is more sensitive to inhibi-
tion by CPFO than AChE (Amitai et al., 1998; Kousba et al., 2003;
Timchalk et al., 2002). Across the current data sets, there were a
few occurrences when samples collected at the same time showed
RBC ChE inhibition that exceeded plasma ChE inhibition; however,
this was in a minority of cases and when it occurred, RBC and plas-
ma ChE samples were similar. Thus, the signiﬁcant inhibition of
RBC ChE in adult females at 0.1 mg/kg/day, which occurred in the
absence of signiﬁcant plasma ChE inhibition, was deemed
spurious.
Overall, the dose–response for ChE inhibition with repeated CPF
exposure in the current study was consistent with three previous
studies examining CPF-induced ChE inhibition in rats. In a 90-
day repeat-dose dietary CPF study with F344/DuCrl rats, Szabo
et al. (1988) reported a signiﬁcant decrease in RBC and brain cho-
linesterase activities atP1 andP5 mg/kg/day, respectively. In the
adult 28-day dietary immunotoxicity study in CD rats (Boverhof,
personal communication), signiﬁcant RBC and brain cholinesterase
inhibition were seen at similar dose levels (P0.4 and P2 mg/kg/
day CPF, respectively) to the current study. RBC ChE inhibition at
0.4 mg/kg/day CPF was somewhat greater in the immunotoxicity
study (53.7% of control compared with 80.5% at 0.5 mg/kg/day in
the current study), which may have been related to the extended
dosing period in the immunotoxicity study (11 days in the current
study vs. 28 days in the immunotoxicity study) or the difference in
exposure routes (oral gavage in corn oil in the current study vs.
dietary in the immunotoxicity study). In a study by Carr and Nail
(2008), ChE inhibition was measured in multiple areas of the brain
in rat pups dosed daily by gavage from PND 10–16 with 5 mg/kg/
day CPF in corn oil. Brain ChE inhibition ranged from 54% (cerebel-
lum and medulla) to 64% (forebrain) with this dosing paradigm
compared with whole brain ChE inhibition that ranged from 59%
to 68% at 3.5 mg/kg/day from PND 11–21 in the current study.
These results show comparable brain ChE inhibition despite slight
differences in dose and exposure duration.
With CPFO exposure, brain ChE was not inhibited in either
adults or pups at any dose level tested, despite similar sensitivity
at both ages to CPFO inhibition of RBC and plasma ChE. These data
indicate a lack of systemic bioavailability of CPFO to peripheral tis-
sues (Bartels et al., 2011) and suggest that exposure to CPFO is less
toxic to brain ChE than exposure to parent CPF. In preliminary
studies, doses 610 mg/kg CPFO did not inhibit brain ChE activity
in adult female rats (Table 2). This ﬁnding differs from Betancourt
and Carr (2004) who reported 50–60% decreases in brain ChE in
newborn rats (PND 1–6) exposed daily to 0.25 or 0.35 mg/kg/day
CPFO via oral gavage. These results may differ from the current
study because the pups were younger at the time of exposure;
therefore, an incomplete blood–brain barrier and/or slower detox-
iﬁcation pathways for CPFO may have contributed to brain ChE
inhibition. However, this PND 1–10 age range has generally been
considered to be physiologically more consistent to human fetuses
in utero (US EPA, 2011) and therefore, would not be relevant for
evaluation of neonatal human exposures.
In conclusion, both the acute and repeated-dose data indicate
that young animals are not more sensitive than adults to CPF or
CPFO over the lower portion of the dose response curves. This
conclusion has been conﬁrmed subsequently using Benchmark
Dose Modeling (Reiss et al., 2012). Thus, with low-level, environ-
mentally relevant exposures, higher sensitivity of young animals
to ChE inhibition would be unlikely. Furthermore, there is no indi-
cation of altered brain ChE activity in either pups or adults follow-
ing 11 daily exposures to <0.5 mg/kg/day CPFO, the proximate
toxicant with CPF exposure. These data suggest that there shouldbe little, if any, concern for CPFO-mediated brain ChE inhibition
at environmentally relevant exposure levels.
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